Oppenheimer analysts said that Radware could be negotiating a licensing agreement with Juniper Networks (JNPR)."Based on our checks we believe Radware is in advanced negotiations with Juniper for a software licensing deal," Oppenheimer analysts wrote in a report Tuesday. "In our opinion, Juniper is looking to license Radware's ADC engine and integrate it with its own data center switch architecture, the QFabric. While details are still limited, we believe the deal could be substantial in size (~$70M- $100M) and over a long time frame (3-5 years). We note that Juniper and Radware have already announced a relationship in 4Q11 to sell Radware's ADC solution on Juniper's MX routers targeting the service provider market. Should the transaction materialize, we see ~$0.75 in EPS upside per annum for Radware at the midpoint of our estimates. Maintain Outperform." Shares of Radware hit a 52-week high Wednesday of $40.83. The stock's 52-week low of $18.98 was set on Oct. 3. Radware's forward P/E is 19.66; the average for telecommunications equipment companies is 11.16. All four of the analysts who cover Radware rated it buy. The stock has risen 34.05% year to date.
BioMarin Pharmaceutical "BioMarin ended the quarter with total revenue of $116.2 million, in‐line enough with consensus of $118.8 million," Brean Murray Carret analysts wrote in an April 27 report. "Naglazyme revenue was $68 million, beating consensus of $60 million, primarily because of the Brazilian order that continues to be in the first quarter versus the fourth of the prior year. Kuvan sales were $32 million, which just beat consensus of $31 million. Aldurazyme worldwide net revenue was $45.9 million, with BioMarin only receiving $12 million, due to negative product transfer revenue of $6.4 million that will reverse in 2H12. The 1Q12 diluted GAAP EPS was $(0.21), which missed consensus of $(0.15), primarily due to higher than expected R&D expenses of $73.8 million, which was mainly due to GALNS manufacturing expenses and additional patients in the GALNS trial, all of which reflects physician optimism for the trial. The company ended 1Q12 with $288 million in cash and investments." Shares of BioMarin hit a 52-week high on Wednesday of $39.20. The stock's 52-week low of $23.74 was set on Aug. 8. Fourteen of the 18 analysts who cover BioMarin rated it buy; four analysts gave the stock a hold rating. The stock has risen 11.98% year to date.
>To contact the writer of this article, click here: Alexandra Zendrian >To submit a news tip, send an email to: firstname.lastname@example.org. >To follow the writer on Twitter, go to Alexandra Zendrian.